Medserv: Stabilising The Platform

 | May 25, 2017 07:19AM ET

Medserv PLC (MT:MDS) issued an interim report on 22 May that indicates a stabilisation of the outlook for the group. METS appears to be trading strongly and while the onshore base support activities are still depressed, these should progressively recover in the second half. The reaction to the challenged FY16 results and more tempered outlook, while unsurprising, leaves the shares looking increasingly attractive against our fair value estimate of €1.83. There is scope for this discount to reduce as trading improves in H217. A FY18 P/E of 13.0x does not appear overly demanding given the potential for continued recovery and growth thereafter.